Director Ilan Ganot of Solid Biosciences Inc. (NASDAQ: SLDB) disposed of 7,205 common shares on February 4, 2026, raising about $46,413. The shares were sold at prices ranging from $6.28 to $6.60, levels that are close to the stocks trading price of $6.52 on the same date.
The sale was not an ad hoc trade but was carried out pursuant to a pre-arranged automated instruction and was intended to satisfy withholding tax obligations related to the vesting of previously granted restricted stock units. Following the transaction, Ganot retains direct ownership of 99,297 shares in Solid Biosciences. In addition to his direct holdings, he also has indirect ownership of 19,394 shares held in trust and 25,271 shares owned by his wife.
Solid Biosciences currently carries an approximate market capitalization of $508 million and a reported beta of 2.65, indicating above-average price volatility. Over the prior 12 months the stock has appreciated by 126%, although InvestingPro analysis cited in company reporting indicates the shares are slightly overvalued when compared with their Fair Value estimate.
InvestingPro further flags the companys pronounced stock movement alongside its recent rally and points to additional research coverage available through its Pro Research Report, which includes analysis on SLDB among more than 1,400 U.S. equities.
Clinical and regulatory updates
Alongside the insider transaction, Solid Biosciences disclosed several developments in its research and regulatory programs. The company reported dosing 33 participants in its Phase 1/2 INSPIRE DUCHENNE trial, noting that its SGT-003 therapy continues to show a favorable safety profile in that study.
Separately, Solid announced that its investigational gene therapy SGT-212 for Friedreichs ataxia has received Orphan Drug designation from the U.S. Food and Drug Administration. In connection with that program, the firm reported dosing the first participant in the Phase 1b FALCON clinical trial evaluating SGT-212.
Market analysts at Citizens have reiterated a Market Outperform rating for Solid Biosciences, calling out the companys proprietary capsid and unique dystrophin as competitive strengths.
On the public health front, the U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel. That addition is expected to improve early detection and access to treatment, and Solid Biosciences was noted as having played a key role on a steering committee focused on newborn screening for the condition.
Context for investors
The share sale by an insider to cover tax obligations related to vesting RSUs is a routine corporate occurrence. Still, it arrives as the stock has delivered a strong one-year return while maintaining elevated volatility, according to the companys reported metrics. Investors seeking deeper analysis of valuation, performance drivers, and risk may consult the detailed Pro Research Report cited by InvestingPro for further data on SLDB and other covered equities.